LM-302

Phase 3Small molecule

LLaNova Medicines Zhejiang Co., Ltd.

LM-302 is one of 103 small molecule programs targeting Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

TumorRecruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Pancreatic CancerNot yet recruiting

TumorPhase 2

Recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Pancreatic CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

LM-302

LLaNova Medicines Zhejiang Co., Ltd.

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

1 10

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Biliary Tract Cancer

NCT05994001

Phase 3Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06351020

Q3 2028

Phase 2Recruiting

Tumor

NCT05934331

Phase 2Not yet recruiting

Pancreatic Cancer

NCT07108504

Q2 2030

Phase 3Recruiting

Adenocarcinoma

NCT07385703

Clinical

Trials by Indication[1]

Solid Tumors2 trials

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Completed·TTurning Point Therapeutics, Inc.·Phase 1·NCT05001516·17 enrolled

Study of LM-302 in Patients With Advance Solid Tumors

Completed·LLaNova Medicines Zhejiang Co., Ltd.·Phase 1/2·NCT05161390·153 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruiting·LLaNova Medicines Zhejiang Co., Ltd.·Phase 3·NCT06351020·387 enrolled

Tumor1 trial

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Recruiting·LLaNova Medicines Zhejiang Co., Ltd.·Phase 2·NCT05934331·276 enrolled

Pancreatic Cancer1 trial

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07108504·30 enrolled

Patients With Advanced Solid Tumors1 trial

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Completed·LLaNova Australia Pty Limited·Phase 1/2·NCT05188664·20 enrolled

2 more indications

Biliary Tract Cancer1 trial

Two Stage, Multi-center Trial of Candonilimab in Combination With LM-302 for Treatment of Patients With Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Active, not recruiting·SShanghai Zhongshan Hospital·Preclinical·NCT05994001·78 enrolled

Adenocarcinoma1 trial

A Randomized, Open-Label, Multicenter Phase III Study of Tecotabart Vedotin Plus Tislelizumab Versus Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With CLDN18.2-Positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07385703·752 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for LM-302. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LM-302 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LM-302. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LaNova Medicines Zhejiang Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLaNova Medicines Zhejiang Co., Ltd.

LM-302

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Q2 2030

Trials by Indication[1]

Solid Tumors2 trials

Gastroesophageal Junction Adenocarcinoma1 trial

Tumor1 trial

Pancreatic Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Biliary Tract Cancer1 trial

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News